Release Date: 2024-06-12

Immunotherapy in Hodgkin Lymphoma

Ozge Sonmez (Author), Mehmet Sonmez (Author)

Release Date: 2024-06-12

Hodgkin lymphoma (HL) is a B-cell lymphoid malignancy. Although treatment outcomes for HL are generally favorable, relapsed/refractory cases can be challenging to manage. Immunotherapy has emerged as an important treatment option, especially for patients who do not respond to traditional therapies. In this chapter, we focus on immune checkpoint inhibitors. Nivolumab and Pembrolizumab are monoclonal [...]

Media Type
    Buy from

    Price may vary by retailers

    Work TypeBook Chapter
    Published inImmunotherapy in Human Cancers
    First Page107
    Last Page113
    DOIhttps://doi.org/10.69860/nobel.9786053359388.8
    Page Count7
    Copyright HolderNobel Tıp Kitabevleri
    Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

    Hodgkin lymphoma (HL) is a B-cell lymphoid malignancy. Although treatment outcomes for HL are generally favorable, relapsed/refractory cases can be challenging to manage. Immunotherapy has emerged as an important treatment option, especially for patients who do not respond to traditional therapies. In this chapter, we focus on immune checkpoint inhibitors. Nivolumab and Pembrolizumab are monoclonal antibodies that target PD-1, while Ipilimumab targets CTLA-4. By inhibiting the PD-1/PD-L1 pathway, these therapies enable the immune system to recognize and attack cancer cells. The use of immune checkpoint inhibitors has improved outcomes in relapsed/refractory cases. The most common side effects include diarrhea and infusion reactions. Overall, immunotherapy has revolutionized the treatment of HL.

    Ozge Sonmez (Author)
    MD, Assistant Professor, Istanbul Cerrahpasa University
    https://orcid.org/0000-0001-6515-6864
    3Dr. Özge Sönmez Education -Istanbul University Cerrahpaşa Medicine Faculty (English medicine programme)       2014-2020 -Istanbul University, Faculty of Open and Distance Education, 2014-2016 Health Management Work Experience -Istanbul University-Cerrahpaşa, Cerrahapasa Medicine Faculty, Jan 2021-present Department of Internal Medicine -İstanbul-Sarıyer Community Health Center. Nov 2020-Jan

    Mehmet Sonmez (Author)
    MD, Professor, Karadeniz Technical University
    https://orcid.org/0000-0002-3617-9087
    32021 Prof. Mehmer Sönmez Education -Istanbul University Cerrahpaşa Medicine Faculty 1982-1988 Work Experience -Turkish Army as Lieutenant Doctor 1988-1991 - General Practitioner in Kadirli/Adana 1991 -Karadeniz Technical University, Department of Internal Medicine as Resident 1991-1996 -Trabzon Numune Hospital as attending physician 1997-2002 -Karadeniz Technical University, Department of Internal Medicine, 2002-present Division of Hematology He graduated from İstanbul University Cerrahpaşa Faculty of Medicine in 1988. He completed his Internal Medicine and Hematology in Karadeniz Technical University Faculty of Medicine. He has a great number of nationally and internationally published works, papers, book chapters and editorial works. He is also a member of various national and international institutions and organizations. He has been working as an academician responsible for the bone marrow transplant unit, tissue typing laboratory, apheresis unit, flowcytometry and hemostasis laboratories at Karadeniz Technical University Faculty of Medicine since 2009 and still holds his position as the president of the Hematology Department.

    • FDA approves asciminib for Philadelphia chromosome-positive chronic myeloid leukemia | FDA. Accessed May 19, 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-asciminib-philadelphia-chromosome-positive-chronic-myeloid-leukemia

    • Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia - PMC. Accessed May 21, 2024. https://www. ncbi.nlm.nih.gov/pmc/articles/PMC4705612/

    onix_3.0::thothThoth ONIX 3.0
    onix_3.0::project_museProject MUSE ONIX 3.0
    onix_3.0::oapenOAPEN ONIX 3.0
    onix_3.0::jstorJSTOR ONIX 3.0
    onix_3.0::google_booksGoogle Books ONIX 3.0
    onix_3.0::overdriveOverDrive ONIX 3.0
    onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
    csv::thothThoth CSV
    json::thothThoth JSON
    kbart::oclcOCLC KBART
    bibtex::thothThoth BibTeX
    doideposit::crossrefCrossRef DOI deposit
    onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
    marc21record::thothThoth MARC 21 Record
    marc21markup::thothThoth MARC 21 Markup
    marc21xml::thothThoth MARC 21 XML

    Share This Chapter!